Johnson & Johnson (JNJ)

NYSE: JNJ · Real-Time Price · USD
191.17
+0.32 (0.17%)
At close: Oct 15, 2025, 4:00 PM EDT
190.93
-0.24 (-0.13%)
After-hours: Oct 15, 2025, 7:58 PM EDT
0.17%
Market Cap460.40B
Revenue (ttm)92.15B
Net Income (ttm)25.12B
Shares Out 2.41B
EPS (ttm)10.35
PE Ratio18.47
Forward PE17.11
Dividend$5.20 (2.72%)
Ex-Dividend DateNov 25, 2025
Volume9,471,947
Open191.48
Previous Close190.85
Day's Range189.30 - 193.57
52-Week Range140.68 - 194.40
Beta0.39
AnalystsBuy
Price Target197.75 (+3.44%)
Earnings DateOct 14, 2025

About JNJ

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizo... [Read more]

Sector Healthcare
IPO Date Sep 24, 1944
Employees 138,100
Stock Exchange NYSE
Ticker Symbol JNJ
Full Company Profile

Financial Performance

In 2024, Johnson & Johnson's revenue was $88.82 billion, an increase of 4.30% compared to the previous year's $85.16 billion. Earnings were $14.07 billion, a decrease of -59.99%.

Financial Statements

Analyst Summary

According to 16 analysts, the average rating for JNJ stock is "Buy." The 12-month stock price target is $197.75, which is an increase of 3.44% from the latest price.

Price Target
$197.75
(3.44% upside)
Analyst Consensus: Buy
Stock Forecasts

News

J&J faces first UK lawsuits alleging its baby powder caused cancer

Johnson & Johnson is facing the first lawsuits in Britain over allegations that its talc products cause cancer, as it fights tens of thousands of similar claims in the United States.

7 hours ago - Reuters

These Analysts Boost Their Forecasts On Johnson & Johnson After Upbeat Q3 Earnings

Johnson & Johnson (NYSE:JNJ) on Tuesday reported better-than-expected third-quarter earnings on Tuesday.

12 hours ago - Benzinga

Johnson & Johnson Rules Out Big Acquisitions, Reiterates Focus On Small Deals: Analyst

On Tuesday, Johnson & Johnson (NYSE:JNJ) reported a third-quarter 2025 adjusted earnings of $2.80 per share, up 15.7% year over year, beating the consensus of $2.75.

12 hours ago - Benzinga

Johnson & Johnson reveals 2025 sales forecast and plans for its orthopedics business

Johnson & Johnson on Tuesday raised its 2025 sales forecast after reporting quarterly earnings that topped Wall Street expectations, and announced plans to spin off its orthopedics business into a sta...

18 hours ago - Fast Company

'NEVER BEEN STRONGER': Johnson & Johnson leader touts latest innovations

Johnson & Johnson CFO and Executive Vice President Joe Wolk addresses the decision to spin off its orthopedics business, explains its innovations and more on ‘The Claman Countdown.'

1 day ago - Fox Business

Johnson & Johnson (JNJ) Q3 2025 Earnings Call Transcript

Johnson & Johnson (NYSE:JNJ) Q3 2025 Earnings Call October 14, 2025 8:30 AM EDT Company Participants Darren Snellgrove - Vice President of Investor Relations Joaquin Duato - CEO & Chairman Joseph Wol...

1 day ago - Seeking Alpha

Citi (C) Posts Strong Earnings, Stuffed Crust Strengthens DPZ, JNJ Slides

While big banks as a group posted strong earnings, Diane King Hall notes Citigroup (C) as a standout. She talks about how stronger IPO and dealmaking markets added muscle for the company.

Other symbols: CDPZ
1 day ago - Schwab Network

Johnson & Johnson Q3 Earnings Surprise, Icotrokinra Shines Again

Today, Johnson & Johnson released its financial results for Q3 2025, which once again stunned Wall Street. So, sales of Rybrevant/Lazcluze, the 'diamond' in its oncology franchise, reached $198 millio...

1 day ago - Seeking Alpha

Johnson & Johnson to spin off orthopedics unit after raising 2025 sales forecast

Johnson & Johnson on Tuesday lifted its 2025 revenue guidance after posting stronger-than-expected third-quarter earnings and revealed plans to spin off its orthopedics business into a standalone comp...

1 day ago - Invezz

Johnson & Johnson To Separate Orthopedics Business, Boosts Annual Sales Outlook

Johnson & Johnson (NYSE:JNJ) on Tuesday reported a third-quarter 2025 adjusted earnings of $2.80 per share, up 15.7% year over year, beating the consensus of $2.75.

1 day ago - Benzinga

Johnson & Johnson's stock heads for a record after a profit beat and plans for another spinoff

Johnson & Johnson's stock rose toward a record after a beat-and-raise earnings report and announcement of plans to separate its orthopedics business.

1 day ago - Market Watch

J&J CEO Joaquin Duato on Q3 results: We are entering an era of accelerated growth

Johnson & Johnson chairman and CEO Joaquin Duato joins 'Squawk Box' to discuss the company's quarterly earnings results, adding warning labels to its multiple myeloma treatment Carvykti, the decision ...

1 day ago - CNBC Television

J&J Lifts Full-Year Sales Outlook, Fueled by Pharma, Med-Device Gains

Johnson & Johnson raised its full-year sales outlook as it posted gains in both its prescription-drug and medical-device businesses in the latest quarter.

1 day ago - WSJ

Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2025

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Q4 dividend.

1 day ago - Business Wire

J&J to spin off orthopedics business, raises full-year forecast

Johnson & Johnson on Tuesday said it plans to separate its orthopedics business into a standalone company named DePuy Synthes within the next 18 to 24 months, marking its second major spinoff since 20...

1 day ago - Reuters

Johnson & Johnson Announces Intent to Separate Its Orthopaedics Business

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (the “Company”) (NYSE: JNJ) today announced the Company's intent to separate its Orthopaedics business to enhance the strategic and operational ...

1 day ago - Business Wire

Johnson & Johnson said Tuesday it plans to separate its artificial hip and knee business into a stand-alone company to be called DePuy Synthes

The planned separation is the latest move by J&J to slim down in recent years and focus on faster-growing businesses.

1 day ago - WSJ

Johnson & Johnson Reports Q3 2025 Results; Raises 2025 Sales Outlook

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced results for third-quarter 2025. “Johnson & Johnson delivered another strong performance in the third quarter fueled ...

1 day ago - Business Wire

Johnson & Johnson Q3 Preview: With Stock Near All-Time Highs, Here's What To Watch

Health care giant Johnson & Johnson (NYSE:JNJ) has had a good year with its shares trading near all-time highs. The company looks to keep a trend of beating analyst estimates when third-quarter financ...

2 days ago - Benzinga

Johnson & Johnson To Acquire Protagonist? It'd Be A Good Deal To Make

Johnson & Johnson (JNJ) is rumored to be in talks to acquire Protagonist Therapeutics (PTGX), following significant buyout speculation and a 30% PTGX stock surge. PTGX's value is underpinned by its or...

Other symbols: PTGX
3 days ago - Seeking Alpha

US FDA adds boxed warning to J&J, Legend Biotech's cancer therapy

The U.S. Food and Drug Administration on Friday approved labeling changes for Johnson & Johnson and its partner Legend Biotech's blood cancer therapy to include a boxed warning for a potentially fatal...

Other symbols: LEGN
5 days ago - Reuters

Johnson & Johnson recommends shareholders reject “mini-tender” offer by Tutanota

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced that it has received notice of an unsolicited mini-tender offer by Tutanota LLC, a limited liability company establi...

5 days ago - Business Wire

RTW Investments' Rod Wong: Expect more deals in biotech space

Rod Wong, RTW Investments CIO & Managing Director, joins CNBC's 'Money Movers' to discuss J&J's reported interest in buying Protagonist Therapeutics, whether he expects more consolidation in the secto...

Other symbols: PTGXXBI
5 days ago - CNBC Television

Johnson & Johnson In Talks To Acquire Protagonist Therapeutics: Report

Johnson & Johnson (NYSE:JNJ) is reportedly in discussions to acquire Protagonist Therapeutics (NASDAQ:PTGX).

Other symbols: PTGX
5 days ago - Benzinga

Johnson & Johnson in talks to acquire Protagonist Therapeutics, WSJ reports

Johnson & Johnson is in discussions to buy Protagonist Therapeutics , the Wall Street Journal reported on Friday, citing people familiar with the matter.

Other symbols: PTGX
5 days ago - Reuters